GHW International Holds Talks with Vietnam's Ministry of Health to Jointly Map Out Cooperation Blueprint in Pharmaceutical Sector

On March 14, 2025, a delegation led by Mr. Chen Zhaohui, Executive Director of GHW, Mr. Yao Haiyan, Vice President, Mr. Huang Jiafeng, CEO of Silver Nile Global Investments Corporation under GHW, and Mr. Zhao Meng, General Manager of GHW (VIETNAM)CO.,LTD, held in-depth exchanges with the Vice Minister of Vietnam's Ministry of Health as well as representatives from relevant departments including the Drug Administration and the Department of International Cooperation on pharmaceutical cooperation.

During the meeting, GHW Group comprehensively showcased its development achievements and prominent advantages in the pharmaceutical industry. With 30 years of development, GHW has long been deeply engaged in the pharmaceutical sector and established a full-industry chain layout covering pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished drugs.

The Vice Minister of Vietnam's Ministry of Health elaborated on the policies and development plans for the landing of pharmaceutical industrial parks, hoping that GHW  can drive more outstanding Chinese pharmaceutical enterprises to invest and develop in Vietnam.

Both parties discussed the feasibility and paths for traditional medicine, biopharmaceuticals, vaccines, cell and gene therapy, medical devices and equipment to enter the Vietnamese market.

Mr. Chen Zhaohui stated that Vietnam, with its unique geographical location, large population base and gradually improved medical system, has become a highly promising emerging market amid the integrated development of the global pharmaceutical industry. This meeting has laid a solid foundation for bilateral cooperation in the pharmaceutical field, and GHW is fully confident in its layout in the Vietnamese market.

Looking ahead, GHW plans to take this meeting as an opportunity to accelerate its business deployment in Vietnam and promote friendly exchanges and cooperation between China and Vietnam in the pharmaceutical sector.